CHINA MEDICAL UNIVERSITY
🇹🇼Taiwan
Characterisation of Gut Microbiota, Bispectral Index Data and Plasma Kynurenine in Patients Undergoing Thyroid Surgery
Completed
- Conditions
- Sleep Deprivation
- Interventions
- Drug: General anesthesia
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 33
- Registration Number
- NCT03981770
- Locations
- 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China
Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.
Not Applicable
Completed
- Conditions
- Cholecystolithiasis and Thyroid Nodule
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 90
- Registration Number
- NCT03924804
- Locations
- 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China
Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal Cancer
Not Applicable
- Conditions
- Gastrointestinal Cancer
- Interventions
- Diagnostic Test: Next generation sequencing
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 50
- Registration Number
- NCT03915171
- Locations
- 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC
Phase 2
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 80
- Registration Number
- NCT03732001
- Locations
- 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- China Medical University, China
- Registration Number
- NCT03677115
- Locations
- 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China
Comparison of the Duration of Ropivacaine Combined With Dexmedetomidine or Dexamethasone on Paravertebral Block
Phase 4
Completed
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 154
- Registration Number
- NCT03570645
- Locations
- 🇨🇳
Department of Anesthesiology, the First Hospital of China Medical University, Shenyang, Liaoning, China
Traumastem® Versus Surgicel® for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection
Phase 3
Completed
- Conditions
- Liver Hemorrhage
- Interventions
- Combination Product: Traumastem®Combination Product: Surgicel®
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 81
- Registration Number
- NCT03489070
- Locations
- 🇨🇳
Hepatobiliary Surgery Department of the First Hosptial of China Medical University, Shenyang, Liaoning, China
Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer
Phase 2
- Conditions
- Colorectal NeoplasmsDrug Therapy
- Interventions
- Drug: FOLFOXIRI
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 30
- Registration Number
- NCT03487939
- Locations
- 🇨🇳
Liaoning cancer hospital, Shenyang, Liaoning, China
Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer
Phase 2
- Conditions
- Colonic NeoplasmsDrug Therapy
- Interventions
- Drug: FOLFOXIRI
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 30
- Registration Number
- NCT03484195
- Locations
- 🇨🇳
Liaoning Cancer Hospital, Shenyang, Liaoning, China
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
Phase 2
- Conditions
- Rectal NeoplasmsRadiationDrug Therapy
- Interventions
- Drug: FOLFOXIRIRadiation: Short-Course Radiation Therapy(5Gy*5)Drug: XELOX
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 30
- Registration Number
- NCT03484221
- Locations
- 🇨🇳
China Medical University, Shenyang, China
© Copyright 2025. All Rights Reserved by MedPath